- $528.44m
- $335.06m
- 53
- 23
- 84
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 2.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.85% | ||
| Return on Equity | -58.63% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.52 | 1.66 | 0.65 | n/a | n/a | 0.75 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 21st, 2017
- Public Since
- November 3rd, 2023
- No. of Shareholders
- 87
- No. of Employees
- 58
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 32,945,341
- Address
- 345 Park Avenue South, Floor 6, NEW YORK, 10010
- Web
- https://www.lexeotx.com/
- Phone
- +1 2125479879
- Auditors
- KPMG LLP
Similar to LXEO
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 21:48 UTC, shares in Lexeo Therapeutics are trading at $16.20. This share price information is delayed by 15 minutes.
Shares in Lexeo Therapeutics last closed at $16.20 and the price had moved by over the past 365 days. In terms of relative price strength the Lexeo Therapeutics share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Lexeo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Lexeo Therapeutics does not currently pay a dividend.
Lexeo Therapeutics does not currently pay a dividend.
Lexeo Therapeutics does not currently pay a dividend.
To buy shares in Lexeo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $16.20, shares in Lexeo Therapeutics had a market capitalisation of $533.71m.
Here are the trading details for Lexeo Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LXEO
Based on an overall assessment of its quality, value and momentum Lexeo Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lexeo Therapeutics is $22.43. That is 38.46% above the last closing price of $16.20.
Analysts covering Lexeo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.86 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lexeo Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -8.97%.
As of the last closing price of $16.20, shares in Lexeo Therapeutics were trading +12.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lexeo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Lexeo Therapeutics' directors